Background Cardiovascular and kidney outcome trials have shown that sodium-glucose co-
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …

OBJECTIVE Randomized controlled trials have shown kidney-protective effects of sodium–
glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested …

Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2)
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …

Background The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney
failure, particularly the need for dialysis or transplantation or death due to kidney disease, is …

Aim The use of sodium glucose co‐transporter 2 (SGLT2) inhibitors in patients with type 2
diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily …

Aim To conduct a systematic review of observational studies to explore the real‐world
kidney benefits of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors in a large and diverse …

SGLT2 inhibitors may offer benefit beyond diabetes | Nature Reviews Nephrology Skip to main
content Thank you for visiting nature.com. You are using a browser version with limited support …

Background We conducted a systematic review and meta-analysis of the cardiovascular,
kidney, and safety outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among …

Background Sodium–glucose co-transporter 2 (SGLT2) inhibitors may have renal protective
effects in people with impaired kidney function. We assessed the use of SGLT2 inhibitors in …

Objective: To review glucose-lowering efficacy and changes in renal function associated
with sodium-glucose co-transporter 2 (SGLT2) inhibitors among patients with chronic kidney …